A Study of Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

Inclusion Criteria:

• Children 2 to 17 years of age inclusive at screening
• Systemic juvenile idiopathic arthritis (sJIA) according to International League of Associations for Rheumatology (ILAR) classification (2001)
• JADAS-71 score of 3.8 or less and absence of fever (related to sJIA) at screening and baseline
• Neutropenia, thrombocytopenia, or elevated ALT/AST previously experienced on the labeled dose (Q2W) of RoActemra/Actemra at any time
• Must meet one of the following:

Not receiving methotrexate (MTX) or discontinued MTX at least 4 weeks prior to baseline visit, or Taking MTX for at least 12 weeks immediately prior to the baseline visit and on a stable dose of </= 20 mg/m2 for at least 8 weeks prior to the baseline visit, together with either folic acid or folinic acid according to local standard of care

• Not currently receiving oral corticosteroids, or taking oral corticosteroids at a stable dose for a minimum of 2 weeks prior to baseline visit at no more than 10 mg/day or 0.2 mg/kg/day, whichever is less
• Not taking non-steroidal anti-inflammatory drug (NSAIDs), or taking no more than 1 type of NSAID at a stable dose for a minimum of 2 weeks prior to the baseline visit, with the dose being less than or equal to the maximum recommended daily dose

Exclusion Criteria:

• Wheelchair bound or bedridden
• Any other auto-immune, rheumatic disease, or overlap syndrome other than sJIA
• Pregnant or lactating, or intending to become pregnant during study conduct and up to 12 weeks after the last administration of study drug
• Any significant concurrent medical or surgical condition which would jeopardize the patient's safety or ability to complete the trial
• History of significant allergic or infusion reactions to prior RoActemra/Actemra infusion, and/or presence of anti-tocilizumab antibodies at screening
• Inborn conditions characterized by a compromised immune system
• Known HIV infection or other acquired forms of immune compromise
• Any active acute, subacute, chronic or recurrent bacterial, viral, or systemic fungal infection
• History of atypical tuberculosis (TB)
• Active TB requiring treatment within 2 years prior to the screening visit
• Positive for hepatitis B or hepatitis C infection
• Chronic hepatitis, viral or autoimmune
• Significant cardiac or pulmonary disease
• History of or current cancer or lymphoma
• Uncontrolled diabetes mellitus
• History of or concurrent serious gastrointestinal disorders
• History of macrophage activation syndrome (MAS) within 3 months prior to screening visit